Disc Medicine, Inc. (IRON): Depreciation & Amortization
$281.0K
Year ended 2025-12-31
$355.0K
Trailing 12 months to 2026-06-30
+46.7%
3-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $281.0K | +80.1% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $156.0K | +56.0% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $100.0K | +12.4% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $89.0K | +178.1% | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $32.0K | n/a | 2023-03-31, From 2021-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | 2025-12-31 | $281.0K | +80.1% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $4.32M | +14.2% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $16.11M | +535.0% |
| MannKind Corp (MNKD) | 2025-12-31 | $12.28M | +66.7% |
| uniQure N.V. (QURE) | 2025-12-31 | $14.76M | +16.8% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $1.15M | +44.5% |
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $0 | n/a |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $24.24M | +2.6% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $220.0K | +94.7% |
Compare IRON, OCUL, VREOF, MNKD side by side · Screen every company in Pharmaceutical Preparations ↗